Tenaya Therapeutics, Inc. Debt Securities, Available-for-sale, Amortized Cost
Tenaya Therapeutics, Inc. (TNYA) had Debt Securities, Available-for-sale, Amortized Cost of $77.44 million as of 2024-09-30, per its 10-Q filed 2024-11-06.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2024-11-06
- 2024-09-30: Debt Securities, Available-for-sale, Amortized Cost $77.44M.
- 2024-06-30: Debt Securities, Available-for-sale, Amortized Cost $97.48M.
- 2024-03-31: Debt Securities, Available-for-sale, Amortized Cost $121.64M.
- 2023-12-31: Debt Securities, Available-for-sale, Amortized Cost $104.03M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2024-09-30 | $77.44M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $97.48M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $121.64M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $104.03M 10-Q · filed 2024-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |